27 Aug 2021

Epimune receives funding from German Ministry of Education and Research for the development of its i.Mune NEO test for early detection of inborn errors of immunity in newborns.

09 Aug 2021

New Article on using Epimune's epigenetic immune cell quantification as a second-tier test to reduce non-actionable secondary findings and false positive referrals in newborn screening for severe combined immunodeficiency published in Journal of Clinical Immunology

14 Apr 2021

Epimune's clinical collaborators at the The Center for Chronic Immunodeficiency (CCI) of the Medical Center - University of Freiburg (Germany) and the Leiden University Medical Center (Netherlands) are presenting their data using Epimune's epigenetic immune cell quantification technology at the 2021 CIS Virtual Annual Meeting.

29 Jan 2021

WHO includes lymphocyte subset enumeration tests in its Essential Diagnostics list (EDL)


27 Jan 2021

Epimune GmbH and Tanner Pharma Group enter into Distribution Partnership for Latin America

26 Jan 2021

Epimune's collaborators at Leiden University Medical Center (LUMC) to present data on epigenetic immune cell quantification as a second tier test in SCID newborn screening at the ISNS-UKNSLN SCID meeting (26/27 Jan 2021; online)

11 Jan 2021

Epimune's collaborators at Leiden University Medical Center (LUMC) nominated for ZonMW Medical Inspirator Award 2020.

16 Oct 2020

Epimune Registers i.Mune TBNK Test as CE-IVD for Dried Blood Spot (DBS) Testing

Second CE-IVD registration within 3 months. Significant expansion of applicability for Epimune's i.Mune TBNK test.

15 Oct 2020

Epimune's collaboration partner at Leiden University Medical Center (LUMC) selected for oral presentation at 19th Biennial Meeting of The European Society of immunodeficiencies (ESID)
LUMC to present recent data of an ongoing study using Epimune's epigenetic immune cell quantification technology in newborn screening for SCID. See more at:


Epimune is also participating as an exhibitor at the (virtual) event.

18 Aug 2020

Epimune and VISICORT Start Collaboration on Corneal Transplant Rejection
Epimune and VISICORT, a multi-disciplinary project funded by the European Union’s Seventh Framework Programme, today announced the initiation of a collaborative immune profiling study with the goal to predict rejection of corneal transplants.

08 July 2020

Epimune completes CE-marking of first IVD product


Epimune today completed CE-marking of its first in vitro diagnostic (IVD) test, the i.Mune TBNK Test, with the signing of the declaration of conformity and registration with the German Institute for Medical Documentation and Information (DIMDI).

06 July 2020

Evonik and Epimune join forces to study the influence of food on the immune system

12 June 2020

Studies show - immune cell quantification allows prognosis of COVID-19 disease

Increasing evidence points at differences in certain lymphocyte subsets in patients with severe vs. mild COVID-19 course of disease. Find out here, how Epimune's i.Mune™ TBNK test may help in monitoring corona virus infected patients.

28 May 2020

Epimune starts crowdinvestment campaign on Seedmatch (German only)

Today, Epimune starts a crowdinvestment campaign on Seedmatch to support further development of its i.Mune™ NEO newborn screening test for inborn errors of immunity (German only).

20 Feb 2020

Epimune receives EN ISO 13485:2016 certification

Berlin, Germany -Epimune today announces the successful certification of its Quality Management System according to the EN ISO 13485:2016 standard. 


"This is a major milestone for our company" says Epimune CEO Dr. Uwe Staub. "Thanks to the coordinated efforts of the team we were able to establish our Quality Management system in record time. We are now on track for the CE-IVD marking of our first product - i.Mune™ TBNK - later this year".